Dec 06, 2019
New recommendations for acute musculoskeletal pain treatment in Denmark
In early November 2019, the Efforts for Rational Pharmacotherapy (IRF), department of the Danish Health Authority (Sundhedsstyrelsen), sent new recommendations for the selection of drugs for the treatment of acute musculoskeletal pain for public consultation.

Musculoskeletal pain is usually caused by different disturbances in the movement apparatus functioning, e.g., overloads, trauma, degenerative diseases, and inflammation. The new recommendations provide general practitioners with an up-to-date basis for the medical treatment of patients with acute musculoskeletal pain.

The endorsed medicines include paracetamol, NSAIDs, opioids, as well as a line of drug combinations, inter alias oxycodone and naloxone, ketobemidone, and dimethylaminodiphenylbutene, codeine and paracetamol, etc.

These recommendations can support the physician in the choice of the drug within the individual drug groups (e.g. long-acting opioids or NSAIDs) that benefit the patients most. The recommendations are included in the National Recommendation List (NRL), which provides help in deciding whether to choose a drug within a given drug group for a specific patient group. The price of drugs, or their reimbursement status, are not included in the assessment. The IRF of the Danish Health Authority has prepared the recommendations in collaboration with a number of external specialists.

The recommendations are in consultation until November 29, 2019.

The full details in Danish can be found here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.
This website uses cookies to ensure you get the best experience on our website. By carrying on browsing, you are giving your consent for us to set cookies.

Learn more
Ok, I agree
Subscribe to newsletter
Subscribe to our newsletter to get regular updates from us on the changes of reimbursement systems (>100 reimbursement stakeholders in 12 EU countries)